A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease.

Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Latrepirdine (Primary) ; Memantine
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms CONSTELLATION
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Oct 2012 Primary endpoint amended as reported by ClinicalTrials.gov. (Parent trial: NCT00912288)
    • 01 Oct 2012 Primary endpoint amended as reported by ClinicalTrials.gov. (Parent trial: NCT00912288)
    • 17 Jul 2012 Actual patient number changed from 89 to 86 as reported by ClinicalTrials.gov. (Parent trial: NCT00912288)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top